MX2016009102A - Composiciones de enolasa 1 (eno1) y sus usos. - Google Patents

Composiciones de enolasa 1 (eno1) y sus usos.

Info

Publication number
MX2016009102A
MX2016009102A MX2016009102A MX2016009102A MX2016009102A MX 2016009102 A MX2016009102 A MX 2016009102A MX 2016009102 A MX2016009102 A MX 2016009102A MX 2016009102 A MX2016009102 A MX 2016009102A MX 2016009102 A MX2016009102 A MX 2016009102A
Authority
MX
Mexico
Prior art keywords
subject
eno1
enolase
diabetes
blood glucose
Prior art date
Application number
MX2016009102A
Other languages
English (en)
Inventor
Rajin Narain Niven
Sarangarajan Rangaprasad
K Vishnudas Vivek
Jing Enxuan
GESTA Stephane
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of MX2016009102A publication Critical patent/MX2016009102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)

Abstract

La invención proporciona las composiciones que contienen Eno1 para la entrega a un músculo. Además, la invención proporciona un método para normalizar la glucosa en sangre en un individuo con glucosa elevada en sangre, el método consiste en administrar al individuo enolasa 1 (Eno1), normalizando de este modo la glucosa en sangre del individuo. La invención también proporciona los métodos de tratamiento de uno o más estados que incluyen alteración de la tolerancia a la glucosa, resistencia a la insulina, prediabetes y diabetes, especialmente diabetes tipo 2, en un individuo, que consiste en administrar al individuo enolasa 1 (Eno1), tratando de este modo el estado en el individuo. En ciertos métodos de la invención el compuesto Eno1 se entrega al músculo.
MX2016009102A 2014-01-13 2015-01-13 Composiciones de enolasa 1 (eno1) y sus usos. MX2016009102A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461926913P 2014-01-13 2014-01-13
US201462009783P 2014-06-09 2014-06-09
US201562100881P 2015-01-07 2015-01-07
PCT/US2015/011275 WO2015106295A2 (en) 2014-01-13 2015-01-13 Enolase 1 (eno1) compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2016009102A true MX2016009102A (es) 2016-09-09

Family

ID=53524434

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009102A MX2016009102A (es) 2014-01-13 2015-01-13 Composiciones de enolasa 1 (eno1) y sus usos.

Country Status (14)

Country Link
US (4) US10188708B2 (es)
EP (2) EP3094341B1 (es)
JP (2) JP6644006B2 (es)
KR (1) KR20160106175A (es)
CN (3) CN106102835B (es)
AU (2) AU2015204451A1 (es)
BR (1) BR112016016153A2 (es)
CA (2) CA2936694A1 (es)
EA (1) EA201691420A1 (es)
HK (2) HK1231394A1 (es)
IL (1) IL246720A0 (es)
MX (1) MX2016009102A (es)
SG (1) SG11201605698XA (es)
WO (2) WO2015106295A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106102835B (zh) 2014-01-13 2020-11-03 博格有限责任公司 烯醇酶1(eno1)组合物及其用途
WO2016210008A1 (en) * 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
AU2017278261A1 (en) 2016-06-05 2019-01-31 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
CN107991493B (zh) * 2017-11-22 2020-03-31 中国医科大学附属第一医院 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用
CN112111462B (zh) * 2020-09-14 2022-08-23 兰州大学 烯醇化酶eno1单克隆抗体及其应用
WO2023093822A1 (en) * 2021-11-26 2023-06-01 Hunilife Biotechnology, Inc. Methods to regulate glycolysis via targeting extracellular alpha-enolase for treating human diseases
CN114533902A (zh) * 2022-02-28 2022-05-27 河南师范大学 一种过表达lrrc15基因的质粒载体及其制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244576T1 (de) 1992-09-25 2003-07-15 Neorx Corp Therapeutischer inhibitor der vaskulären glatten muskelzellen
EP0787147A1 (en) 1994-10-25 1997-08-06 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US20030044795A1 (en) 1996-09-06 2003-03-06 Inger Byrajalsen Biochemical markers of the human endometrium
US7078375B1 (en) * 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US6329501B1 (en) 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
EP1238072A2 (en) 1999-09-01 2002-09-11 Subsidiary N0. 3, INC. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2001016323A2 (en) 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CA2389834A1 (en) 1999-10-25 2001-05-03 Monica Mody Genetic sequences associated with neural cell proliferation and disease
CA2399058A1 (en) 2000-02-02 2001-08-09 Transgene S.A. Targeting peptides
US20030203372A1 (en) 2000-12-08 2003-10-30 Ward Neil Raymond Analysis method
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
US20040058326A1 (en) 2001-07-27 2004-03-25 Brooksbank Robert Alan Identification and use of molecules implicated in pain
US20050191627A1 (en) 2001-09-28 2005-09-01 Incyte Corporation Enzymes
WO2003064501A1 (en) 2002-01-31 2003-08-07 Clarke Slemon Conformationally restricted compounds as dendrimer cores
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
JP2004081111A (ja) * 2002-08-27 2004-03-18 Yamaguchi Technology Licensing Organization Ltd 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法
JP2006516094A (ja) 2002-11-08 2006-06-22 ジェネンテック・インコーポレーテッド ナチュラルキラー細胞関連疾患の治療のための組成物と方法
CN100446772C (zh) * 2002-12-06 2008-12-31 法布罗根股份有限公司 一种稳定HIFα的制剂在制备治疗糖尿病的药物中的应用
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
AU2003294828A1 (en) 2002-12-17 2004-07-09 Sinogenomax Co. Ltd. Chinese National Human Genomecenter Specific markers for pancreatic cancer
AU2003300178A1 (en) 2002-12-30 2004-07-29 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2004084950A2 (en) 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005073621A (ja) 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
CA2540529C (en) 2003-10-03 2012-03-13 Vib Vzw Means and methods for the recruitment and identification of stem cells
US8133733B2 (en) * 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
JP2006528361A (ja) 2004-07-06 2006-12-14 クンイル ファーマシューティカル カンパニー リミテッド アルドラーゼを含む網膜血管疾患診断用組成物およびその診断方法
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
US20080138913A1 (en) * 2005-01-03 2008-06-12 Sook-Yeong Jeon Composition for Prevention, Treatment, and Diagnosis of Chronic Inflammatory Airway Diseases
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
WO2008012362A2 (en) 2006-07-27 2008-01-31 Oxford Genome Sciences (Uk) Ltd New protein isoforms and uses thereof
EA016731B1 (ru) 2006-09-29 2012-07-30 Рибовакс Байотекнолоджиз Са Изоформа человеческой альфа-енолазы, антитело к указанной изоформе и способы их применения
US20100047256A1 (en) 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
WO2008134761A2 (en) 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
AU2008273096B2 (en) 2007-07-12 2013-05-02 Academisch Ziekenhuis Leiden Molecules for targeting compounds to various selected organs or tissues
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
JP5429707B2 (ja) 2008-03-27 2014-02-26 国立大学法人群馬大学 微粒子およびその製造方法
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
CA2849218C (en) 2008-07-18 2016-09-06 Hill's Pet Nutrition, Inc. Compositions and methods for treating disorders associated with overweight animals
EP2194382A1 (en) 2008-12-03 2010-06-09 Universität des Saarlandes An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
US20120309684A1 (en) 2009-11-30 2012-12-06 Isis Innovation Limited Conjugates for delivery of biologically active compounds
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
RU2012157572A (ru) 2010-05-28 2014-07-10 МЕН-ЭнЭрЖ СА Изоформы нейрегулина, полипептиды нейрегулина и их применение
EP2638058B1 (en) 2010-11-12 2017-01-11 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US20140086895A1 (en) 2011-05-10 2014-03-27 Universite De Rouen Methods and pharmaceutical compositions for the treatment of autoimmune diseases
GB201113814D0 (en) 2011-08-10 2011-09-28 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
CN103998458B (zh) 2011-08-30 2018-10-09 医学研究理事会 具有中央疏水域的细胞穿透肽
WO2013090732A2 (en) 2011-12-14 2013-06-20 The Board Of Regents Of The University Of Texas System Collateral gene inactivation biomarkers and targets for cancer therapy
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
CN111544601A (zh) 2012-10-30 2020-08-18 粒子科学有限公司 具有靶向部分的药物递送粒子制剂
CN106102835B (zh) 2014-01-13 2020-11-03 博格有限责任公司 烯醇酶1(eno1)组合物及其用途
WO2016210008A1 (en) 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
CA2992611A1 (en) 2015-07-16 2017-01-19 Berg Llc Enolase 1 (eno1) compositions and uses thereof

Also Published As

Publication number Publication date
CN106102835A (zh) 2016-11-09
EP3094379A4 (en) 2017-06-28
US11224641B2 (en) 2022-01-18
US20150361409A1 (en) 2015-12-17
JP6644006B2 (ja) 2020-02-12
WO2015106296A8 (en) 2015-08-20
WO2015106295A2 (en) 2015-07-16
SG11201605698XA (en) 2016-08-30
CN106659766A (zh) 2017-05-10
AU2015204452A1 (en) 2016-08-11
US20190307863A1 (en) 2019-10-10
CN112336851A (zh) 2021-02-09
EA201691420A1 (ru) 2016-12-30
HK1231394A1 (zh) 2017-12-22
BR112016016153A2 (pt) 2017-12-12
CN106102835B (zh) 2020-11-03
US20190307864A1 (en) 2019-10-10
KR20160106175A (ko) 2016-09-09
JP6629234B2 (ja) 2020-01-15
JP2017508000A (ja) 2017-03-23
US20150359861A1 (en) 2015-12-17
CA2936694A1 (en) 2015-07-16
AU2015204451A1 (en) 2016-07-28
EP3094341A4 (en) 2017-11-01
HK1231425A1 (zh) 2017-12-22
WO2015106296A1 (en) 2015-07-16
WO2015106295A3 (en) 2015-11-05
IL246720A0 (en) 2016-08-31
EP3094341A1 (en) 2016-11-23
US10188707B2 (en) 2019-01-29
EP3094341B1 (en) 2019-10-02
JP2017509690A (ja) 2017-04-06
CA2936691A1 (en) 2015-07-16
EP3094379A2 (en) 2016-11-23
US10188708B2 (en) 2019-01-29

Similar Documents

Publication Publication Date Title
MX2016009102A (es) Composiciones de enolasa 1 (eno1) y sus usos.
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
MX2021014709A (es) Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes.
MX2016013243A (es) Agonistas peptídicos duales de los receptores de glp-1/glucagón derivados de la exendina-4.
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
MX362190B (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon.
MX2015008011A (es) Suplementos y sistemas de monitoreo para la dosificacion de los suplementos.
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2018000362A (es) Derivados de exendina-4 como agonistas peptidicos duales selectivos de los receptores de glp-1/glucagon.
PH12017501486A1 (en) Nasal powder formulation for treatment of hypoglycemia
PH12019502655A1 (en) Acylated insulin compound
PH12017500017A1 (en) A combination of vitamin d and zinc and its use
MX2016000220A (es) Regulacion del metabolismo de glucosa usando anticuerpos anti-cgrp.
WO2014049438A3 (en) Method of non-invasive determination of glucose concentration in blood and device for the implementation thereof
MX2017009313A (es) Formulaciones intravenosas de baclofeno y metodos de tratamiento.
PH12017500084A1 (en) Vitamin b2 and its use
MX2017000878A (es) Peptidos marinos y nucleotidos de pescado, composiciones y sus usos para reducir la glucosa en la sangre.
WO2018106982A8 (en) COMPOSITIONS AND METHODS FOR IMPROVING THE MATURATION, HEALTH AND FUNCTION OF BETA CELLS
MX2018004656A (es) Baclofeno intravenoso y metodos de tratamiento.
SG10201809418VA (en) New administration routes of insulin, insulin analogs or derivatives of insulin
MX2017012231A (es) Secuencias de oligonucleotidos dirigidos al factor de transcripcion tsc22d4 para el tratamiento de la resistencia a la insulina.
Leguay Allergic reaction: case report
Spring Fatigue, nausea, elevated liver enzymes: case report
Henao Type I hypersensitivity: case report